Cargando…

Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin

Patients with primary immunodeficiency diseases often require lifelong immunoglobulin (IG) therapy. Most clinical trials investigating IG therapies characterize serum immunoglobulin G (IgG) pharmacokinetic (PK) profiles by serially assessing serum IgG levels. This retrospective analysis evaluated wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zhaoyang, McCoy, Barbara, Engl, Werner, Yel, Leman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310849/ https://www.ncbi.nlm.nih.gov/pubmed/34036490 http://dx.doi.org/10.1007/s10875-021-00990-z

Ejemplares similares

Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America
por: Suez, Daniel, et al.
Publicado: (2016)

Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases
por: Li, Zhaoyang, et al.
Publicado: (2023)

Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies
por: Borte, M., et al.
Publicado: (2016)

Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials
por: Meckley, Lisa M., et al.
Publicado: (2020)

Transient IgA, steady IgG?
por: Berthold, Dorothée L., et al.
Publicado: (2020)

Immune Globulin Subcutaneous (Human) 20%: In Primary Immunodeficiency Disorders
por: McCormack, Paul L.
Publicado: (2012)

Selective IgA Deficiency
por: Yel, Leman
Publicado: (2010)

Higher Doses of Subcutaneous IgG Reduce Resource Utilization in Patients with Primary Immunodeficiency
por: Haddad, Elie, et al.
Publicado: (2011)

Pharmacokinetics and Biochemical Efficacy of an α(1)-Proteinase Inhibitor (Aralast NP) in α(1)-Antitrypsin Deficiency: a Cross-Product Retrospective Comparability Analysis
por: Li, Zhaoyang, et al.
Publicado: (2022)

Quality of Life Evaluation in Saudi Arabian Pediatric Patients with Primary Immunodeficiency Diseases Receiving 20% Subcutaneous IgG Infusions at Home
por: Al-Saud, Bandar, et al.
Publicado: (2023)

Bioavailability of IgG Administered by the Subcutaneous Route
por: Berger, Melvin, et al.
Publicado: (2013)

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2016)

Management of common variable immunodeficiency by subcutaneous IgG self‐administration during pregnancy – a case report
por: Marasco, Carolina, et al.
Publicado: (2017)

Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: A systematic review and meta-analysis of clinical studies()
por: Shrestha, Pragya, et al.
Publicado: (2019)

Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis
por: Newkirk, Marianna M, et al.
Publicado: (2003)

TOLERANCE AND IMMUNITY TO MATERNALLY DERIVED INCOMPATIBLE IgG(2a)-GLOBULIN IN MICE
por: Warner, Noel L., et al.
Publicado: (1970)

Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
por: Suez, Daniel, et al.
Publicado: (2017)

A Novel Targeted Screening Tool for Hypogammaglobulinemia: Measurement of Serum Immunoglobulin (IgG, IgM, IgA) Levels from Dried Blood Spots (Ig-DBS Assay)
por: Yel, Leman, et al.
Publicado: (2015)

Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency
por: Kuster, John K., et al.
Publicado: (2022)

Acute pericarditis in a young patient with IgG immunodeficiency
por: Skowerski, Tomasz, et al.
Publicado: (2020)

Analysis of differences between total IgG and sum of the IgG subclasses in children with suspected immunodeficiency – indication of determinants
por: Pasternak, Gerard, et al.
Publicado: (2018)

Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy
por: Alsolaihim, Alanood, et al.
Publicado: (2020)

Trough Concentrations of Specific Antibodies in Primary Immunodeficiency Patients Receiving Intravenous Immunoglobulin Replacement Therapy
por: Hassin, Ori, et al.
Publicado: (2021)

Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation
por: Horinaka, Shigeo, et al.
Publicado: (2017)

Pharmacokinetic Models for FcRn-Mediated IgG Disposition
por: Xiao, Jim J.
Publicado: (2012)

Mechanisms of Obesity-Induced Changes in Pharmacokinetics of IgG in Rats
por: Gao, Xizhe, et al.
Publicado: (2023)

SERUM TOTAL IgG AND TETANUS SPECIFIC IgG IN NIGERIAN HUMAN IMMUNODEFICIENCY VIRUS INFECTED PRIMIGRAVIDAE AND THE CORD BLOOD OF THEIR BABIES AT BIRTH
por: Fatokun, M.O., et al.
Publicado: (2019)

Does the Tacrolimus Trough Level Adequately Predict Drug Exposure in Patients Requiring a High Tacrolimus Dose?
por: Haverals, Lien, et al.
Publicado: (2023)

Allergen-Specific IgE and IgG4 as Biomarkers for Immunologic Changes during Subcutaneous Allergen Immunotherapy
por: Nikolov, Georgi, et al.
Publicado: (2021)

FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye
por: Kim, Hyuncheol, et al.
Publicado: (2009)

Subclasses of allergen-specific IgG: Serum IgG2 and IgG3 levels are not predicted by IgG1/IgG4 levels
por: MacGlashan, Donald, et al.
Publicado: (2021)

Development of common variable immunodeficiency in IgA- and IgG2-deficient patients with systemic lupus erythematosus
por: Suyama, Kazuhide, et al.
Publicado: (2011)

The case report of MOG and NMDAR IgG double positive encephalitis treated with subcutaneous ofatumumab
por: Zhang, Rui, et al.
Publicado: (2023)

Common variable immunodeficiency associated with microdeletion of chromosome 1q42.1-q42.3 and inositol 1,4,5-trisphosphate kinase B (ITPKB) deficiency
por: Louis, Ankmalika G, et al.
Publicado: (2016)

The antiinflammatory activity of IgG: the intravenous IgG paradox
por: Nimmerjahn, Falk, et al.
Publicado: (2007)

Serum IgG4 levels outperform IgG4/IgG RNA ratio in differential diagnosis of IgG4-related disease
por: Schulte, Lucas A., et al.
Publicado: (2020)

Enriched blood IgG sialylation attenuates IgG-mediated and IgG-controlled-IgE-mediated allergic reactions
por: Petry, Janina, et al.
Publicado: (2020)

Association of dengue infection with anti-alpha-gal antibodies, IgM, IgG, IgG1, and IgG2
por: Olajiga, Olayinka M., et al.
Publicado: (2022)

Clinical and Pharmacokinetic Outcomes of Peak–Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial
por: Al-Sulaiti, Fatima Khalifa, et al.
Publicado: (2019)

Is subcutaneous insulin administration adequate for the management of hyperglycemic crisis in COVID-19?
por: Permana, Hikmat, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kekthrhuln3t22l6gkvjv8c6sp